Squamous Cell Carcinoma of Head and Neck Clinical Trials in Cleveland, Ohio

3 studies are recruiting for squamous cell carcinoma of head and neck in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

    The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    56 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06385080 on ClinicalTrials.gov

  2. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    158 in total
    Run by
    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

  3. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    20 in total
    Run by
    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.